Midatech Pharma PLC-ADR (NASDAQ:MTP) – Analysts at Zacks Investment Research cut their FY2017 EPS estimates for Midatech Pharma in a note issued to investors on Wednesday. Zacks Investment Research analyst D. Bautz now anticipates that the company will post earnings per share of ($0.43) for the year, down from their previous forecast of ($0.42). Zacks Investment Research also issued estimates for Midatech Pharma’s Q4 2017 earnings at ($0.10) EPS, FY2018 earnings at ($0.33) EPS and FY2019 earnings at ($0.33) EPS.

Midatech Pharma (MTP) opened at $0.96 on Monday. The company has a current ratio of 1.62, a quick ratio of 1.49 and a debt-to-equity ratio of 0.03. Midatech Pharma has a one year low of $0.79 and a one year high of $3.27.

ILLEGAL ACTIVITY WARNING: “Research Analysts Set Expectations for Midatech Pharma PLC-ADR’s FY2017 Earnings (MTP)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/03/12/research-analysts-set-expectations-for-midatech-pharma-plc-adrs-fy2017-earnings-mtp.html.

About Midatech Pharma

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.